Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

分子刷偶联反义寡核苷酸作为泛 KRAS 耗竭剂

• 批准号: 10771051
• 负责人: Ke Zhang
• 金额: $ 5.5万
• 依托单位: PACDNA LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10771051
• 关键词: Acceleration; Animal Model; Antisense Oligonucleotides; Automobile Driving; Cells; Clinic; Drug Kinetics; Goals; Human; KRAS2 gene; Lung; Malignant Epithelial Cell; Malignant Neoplasms; Marketing; Methods; Modality; Molecular; Monkeys; Mus; Mutate; Mutation; Nucleic Acids; Oncogenes; Oncoproteins; Pharmaceutical Preparations; Pharmacology Study; Pharmacology and Toxicology; Phase; Plasma; Proteins; Refractory; Research; Structure; Technology; Therapeutic Agents; Therapeutic Intervention; Translating; Xenograft Model; dosage; improved; in vivo; inhibitor; mouse model; mutant; nonhuman primate; novel; nucleic acid-based therapeutics; patient derived xenograft model; pharmacologic; pre-clinical; side effect; small molecule; tumor; uptake

Project Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeutic intervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a single mutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitors has heightened the importance of alternative methods targeting the oncogene. One such strategy involves therapeutic nucleic acids, which make it possible to deplete target proteins that are intractable to conventional drug modalities. We have developed a novel form of nucleic acid therapeutics, termed Brushield™ conjugate, which substantially enhances the antitumor activity of antisense oligonucleotides by elevating in vivo stability, accelerating cellular uptake, and improving plasma pharmacokinetics and tumor accumulation, allowing for a much lower dosage to be used compared to conventional methods. The conjugate also suppresses nearly all side effects associated with traditional nucleic acid drugs by reducing unwanted nucleic acid-protein interactions. The goal of this proposal is to lay the groundwork for translating the technology towards the clinic. In Phase I, we will optimize the structure of the Brushield™ conjugate, and enhance current indication using a panel of non-small cell lung cells and mouse xenograft models. Upon reaching set quantitative milestones, we will subject the conjugate to more relevant animal models (orthotopic and patient-derived xenograft models), and perform tolerability and pharmacokinetic studies in mice and monkeys (Phase II). These studies will allow us to pursue an IND filing at the end of the project.

项目摘要/摘要 KRAS的突变形式是人类肿瘤的关键驱动力，但仍部分难治性治疗 干涉。经过三十多年的研究，只有一个针对单个抑制剂（索托拉西） 突变（KRASG12C）已进入市场。开发小分子kras抑制剂的困难 已经提高了针对癌基因的替代方法的重要性。一种这样的策略 涉及热核酸，这使得复制与与 常规药物方式。我们已经开发了一种新型的核酸治疗形式，称为 Brushield™结合物，可大大增强反义寡核苷酸的抗肿瘤活性 通过提高体内稳定性，加速细胞摄取，并改善血浆药代动力学和 与常规方法相比，肿瘤的积累允许使用较低的剂量。 共轭还抑制了几乎所有与传统核酸药物相关的副作用 减少不需要的核酸蛋白质相互作用。该提议的目的是奠定基础 用于将技术转换为诊所。在第一阶段，我们将优化 Brushield™结合物，并使用一组非小细胞肺细胞和 鼠标Xenographic模型。达到设定的定量里程碑后，我们将进行共轭 更相关的动物模型（矫形和患者衍生的Xenograpony模型），并执行耐受性 小鼠和猴子的药代动力学研究（II期）。这些研究将使我们能够追求 在项目末尾提交的IND。